0 XP   0   0   0

Concord Drugs Ltd
Buy, Hold or Sell?

Should you buy, hold or sell Concord Drugs Ltd?

I guess you are interested in Concord Drugs Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Concord Drugs Ltd

Let's start. I'm going to help you getting a better view of Concord Drugs Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Concord Drugs Ltd even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Concord Drugs Ltd is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Concord Drugs Ltd. The closing price on 2023-02-03 was INR30.20 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Concord Drugs Ltd Daily Candlestick Chart
Concord Drugs Ltd Daily Candlestick Chart
Summary









1. Valuation of Concord Drugs Ltd




Current price per share

INR30.20

2. Growth of Concord Drugs Ltd




Is Concord Drugs Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$3.4m$3.2m$192.9k5.6%

How much money is Concord Drugs Ltd making?

Current yearPrevious yearGrowGrow %
Making money$192.9k$397k-$204.1k-105.8%
Net Profit Margin2.7%6.4%--

How much money comes from the company's main activities?

3. Financial Health of Concord Drugs Ltd




Comparing to competitors in the industry




  Industry Rankings ()  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Concord Drugs Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Concord Drugs Ltd earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • A Net Profit Margin of 2.7% means that ₹0.03 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Concord Drugs Ltd:

  • The MRQ is 2.7%. The company is making a profit. +1
  • The TTM is 2.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.7%TTM2.7%0.0%
TTM2.7%YOY6.4%-3.7%
TTM2.7%5Y2.6%+0.1%
5Y2.6%10Y2.6%0.0%
1.1.2. Return on Assets

Shows how efficient Concord Drugs Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • 2.8% Return on Assets means that Concord Drugs Ltd generated ₹0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Concord Drugs Ltd:

  • The MRQ is 2.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.8%TTM2.8%0.0%
TTM2.8%YOY6.6%-3.8%
TTM2.8%5Y2.6%+0.2%
5Y2.6%10Y2.6%0.0%
1.1.3. Return on Equity

Shows how efficient Concord Drugs Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • 5.6% Return on Equity means Concord Drugs Ltd generated ₹0.06 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Concord Drugs Ltd:

  • The MRQ is 5.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.6%TTM5.6%0.0%
TTM5.6%YOY12.3%-6.6%
TTM5.6%5Y5.3%+0.4%
5Y5.3%10Y5.3%0.0%

1.2. Operating Efficiency of Concord Drugs Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Concord Drugs Ltd is operating .

  • Measures how much profit Concord Drugs Ltd makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Concord Drugs Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y2.0%-2.0%
5Y2.0%10Y2.0%0.0%
1.2.2. Operating Ratio

Measures how efficient Concord Drugs Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 1.56 means that the operating costs are ₹1.56 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Concord Drugs Ltd:

  • The MRQ is 1.559. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.559. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.559TTM1.5590.000
TTM1.559YOY1.786-0.227
TTM1.5595Y1.728-0.168
5Y1.72810Y1.7280.000

1.3. Liquidity of Concord Drugs Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Concord Drugs Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 1.83 means the company has ₹1.83 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Concord Drugs Ltd:

  • The MRQ is 1.833. The company is able to pay all its short-term debts. +1
  • The TTM is 1.833. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.833TTM1.8330.000
TTM1.833YOY1.858-0.025
TTM1.8335Y1.601+0.231
5Y1.60110Y1.6010.000
1.3.2. Quick Ratio

Measures if Concord Drugs Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • A Quick Ratio of 1.00 means the company can pay off ₹1.00 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Concord Drugs Ltd:

  • The MRQ is 1.001. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.001. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.001TTM1.0010.000
TTM1.001YOY1.070-0.070
TTM1.0015Y0.939+0.061
5Y0.93910Y0.9390.000

1.4. Solvency of Concord Drugs Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Concord Drugs Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Concord Drugs Ltd to industry mean.
  • A Debt to Asset Ratio of 0.50 means that Concord Drugs Ltd assets are financed with 49.8% credit (debt) and the remaining percentage (100% - 49.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Concord Drugs Ltd:

  • The MRQ is 0.498. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.498. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.498TTM0.4980.000
TTM0.498YOY0.463+0.034
TTM0.4985Y0.569-0.072
5Y0.56910Y0.5690.000
1.4.2. Debt to Equity Ratio

Measures if Concord Drugs Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Concord Drugs Ltd to the  industry mean.
  • A Debt to Equity ratio of 99.0% means that company has ₹0.99 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Concord Drugs Ltd:

  • The MRQ is 0.990. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.990. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.990TTM0.9900.000
TTM0.990YOY0.864+0.127
TTM0.9905Y1.475-0.484
5Y1.47510Y1.4750.000

2. Market Valuation of Concord Drugs Ltd

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Concord Drugs Ltd generates.

  • Above 15 is considered overpriced but always compare Concord Drugs Ltd to the  industry mean.
  • A PE ratio of 15.90 means the investor is paying ₹15.90 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Concord Drugs Ltd:

  • The EOD is 16.562. Very good. +2
  • The MRQ is 15.904. Very good. +2
  • The TTM is 15.904. Very good. +2
Trends
Current periodCompared to+/- 
EOD16.562MRQ15.904+0.658
MRQ15.904TTM15.9040.000
TTM15.904YOY7.740+8.164
TTM15.9045Y24.800-8.896
5Y24.80010Y24.8000.000
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Concord Drugs Ltd.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Concord Drugs Ltd:

  • The MRQ is 32.736. Seems overpriced? -1
  • The TTM is 32.736. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ32.736TTM32.7360.000
TTM32.736YOY0.774+31.962
TTM32.7365Y27.209+5.527
5Y27.20910Y27.2090.000

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Concord Drugs Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 0.89 means the investor is paying ₹0.89 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Concord Drugs Ltd:

  • The EOD is 0.931. Very good. +2
  • The MRQ is 0.894. Very good. +2
  • The TTM is 0.894. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.931MRQ0.894+0.037
MRQ0.894TTM0.8940.000
TTM0.894YOY0.949-0.055
TTM0.8945Y0.761+0.133
5Y0.76110Y0.7610.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Concord Drugs Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.8231.8230%3.753-51%8.109-78%8.109-78%
Book Value Growth--1.0601.0600%1.140-7%1.071-1%1.071-1%
Book Value Per Share--32.43532.4350%30.612+6%29.840+9%29.840+9%
Book Value Per Share Growth--1.0601.0600%1.140-7%1.037+2%1.037+2%
Current Ratio--1.8331.8330%1.858-1%1.601+14%1.601+14%
Debt To Asset Ratio--0.4980.4980%0.463+7%0.569-13%0.569-13%
Debt To Equity Ratio--0.9900.9900%0.864+15%1.475-33%1.475-33%
Dividend Per Share----0%-0%-0%-0%
Eps--1.8231.8230%3.753-51%1.617+13%1.617+13%
Eps Growth--0.4860.4860%9.997-95%3.736-87%3.736-87%
Free Cash Flow Per Share--0.8850.8850%-2.354+366%0.278+218%0.278+218%
Free Cash Flow Per Share Growth--2.3762.3760%-1.574+166%0.726+227%0.726+227%
Free Cash Flow To Equity Per Share--0.8850.8850%-2.354+366%0.045+1848%0.045+1848%
Free Cash Flow To Equity Per Share Growth--2.3762.3760%-1.574+166%3.476-32%3.476-32%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.0270.0270%0.064-58%0.026+2%0.026+2%
Operating Margin----0%-0%0.020-100%0.020-100%
Operating Ratio--1.5591.5590%1.786-13%1.728-10%1.728-10%
Pb Ratio0.931+4%0.8940.8940%0.949-6%0.761+17%0.761+17%
Pe Ratio16.562+4%15.90415.9040%7.740+105%24.800-36%24.800-36%
Peg Ratio--32.73632.7360%0.774+4128%27.209+20%27.209+20%
Price Per Share30.200+4%29.00029.0000%29.0500%23.050+26%23.050+26%
Price To Total Gains Ratio16.563+4%15.90515.9050%7.740+105%4.828+229%4.828+229%
Profit Growth--0.4860.4860%9.996-95%3.763-87%3.763-87%
Quick Ratio--1.0011.0010%1.070-6%0.939+7%0.939+7%
Return On Assets--0.0280.0280%0.066-57%0.026+8%0.026+8%
Return On Equity--0.0560.0560%0.123-54%0.053+7%0.053+7%
Revenue Growth--1.1481.1480%1.000+15%1.072+7%1.072+7%
Total Gains Per Share--1.8231.8230%3.753-51%8.109-78%8.109-78%
Total Gains Per Share Growth--0.4860.4860%3.446-86%1.281-62%1.281-62%
Usd Book Value--3431631.4873431631.4870%3238722.300+6%3078478.697+11%3078478.697+11%
Usd Book Value Change Per Share--0.0220.0220%0.045-51%0.098-78%0.098-78%
Usd Book Value Per Share--0.3920.3920%0.370+6%0.361+9%0.361+9%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0220.0220%0.045-51%0.020+13%0.020+13%
Usd Free Cash Flow--93674.60693674.6060%-249054.300+366%26534.402+253%26534.402+253%
Usd Free Cash Flow Per Share--0.0110.0110%-0.028+366%0.003+218%0.003+218%
Usd Free Cash Flow To Equity Per Share--0.0110.0110%-0.028+366%0.001+1848%0.001+1848%
Usd Price Per Share0.365+4%0.3510.3510%0.3520%0.279+26%0.279+26%
Usd Profit--192916.048192916.0480%397085.700-51%169743.262+14%169743.262+14%
Usd Revenue--7133734.2867133734.2860%6214197.000+15%6344319.846+12%6344319.846+12%
Usd Total Gains Per Share--0.0220.0220%0.045-51%0.098-78%0.098-78%
 EOD+2 -3MRQTTM+0 -0YOY+16 -225Y+26 -1310Y+26 -13

3.2. Fundamental Score

Let's check the fundamental score of Concord Drugs Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1516.562
Price to Book Ratio (EOD)Between0-10.931
Net Profit Margin (MRQ)Greater than00.027
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.001
Current Ratio (MRQ)Greater than11.833
Debt to Asset Ratio (MRQ)Less than10.498
Debt to Equity Ratio (MRQ)Less than10.990
Return on Equity (MRQ)Greater than0.150.056
Return on Assets (MRQ)Greater than0.050.028
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Concord Drugs Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.507
Ma 20Greater thanMa 5031.675
Ma 50Greater thanMa 10032.193
Ma 100Greater thanMa 20032.475
OpenGreater thanClose28.050
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets564,451
Total Liabilities280,845
Total Stockholder Equity283,606
 As reported
Total Liabilities 280,845
Total Stockholder Equity+ 283,606
Total Assets = 564,451

Assets

Total Assets564,451
Total Current Assets418,907
Long-term Assets418,907
Total Current Assets
Cash And Cash Equivalents 444
Short-term Investments 210
Net Receivables 228,585
Inventory 174,899
Other Current Assets 2,673
Total Current Assets  (as reported)418,907
Total Current Assets  (calculated)406,811
+/- 12,096
Long-term Assets
Long-term Assets  (as reported)145,545
Long-term Assets  (calculated)0
+/- 145,545

Liabilities & Shareholders' Equity

Total Current Liabilities228,590
Long-term Liabilities52,256
Total Stockholder Equity283,606
Total Current Liabilities
Short Long Term Debt 139,517
Accounts payable 71,788
Other Current Liabilities 10,572
Total Current Liabilities  (as reported)228,590
Total Current Liabilities  (calculated)221,877
+/- 6,713
Long-term Liabilities
Long term Debt 24,826
Long-term Liabilities Other -1
Long-term Liabilities  (as reported)52,256
Long-term Liabilities  (calculated)24,825
+/- 27,431
Total Stockholder Equity
Retained Earnings 135,068
Total Stockholder Equity (as reported)283,606
Total Stockholder Equity (calculated)135,068
+/- 148,538
Other
Capital Stock87,438
Common Stock Shares Outstanding 8,744
Net Debt 163,898
Net Invested Capital 447,949
Net Working Capital 190,317



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
> Total Assets 
0
0
827,685
580,155
498,827
564,451
564,451498,827580,155827,68500
   > Total Current Assets 
602,453
920,191
697,377
455,640
360,110
418,907
418,907360,110455,640697,377920,191602,453
       Cash And Cash Equivalents 
0
0
1,589
121
354
444
4443541211,58900
       Short-term Investments 
0
0
259
259
210
210
21021025925900
       Net Receivables 
460,508
711,723
484,347
254,460
207,280
228,585
228,585207,280254,460484,347711,723460,508
       Inventory 
110,270
186,194
186,415
164,313
118,719
174,899
174,899118,719164,313186,415186,194110,270
       Other Current Assets 
29,331
21,717
24,767
36,488
6,209
2,673
2,6736,20936,48824,76721,71729,331
   > Long-term Assets 
0
0
130,308
124,514
138,717
145,545
145,545138,717124,514130,30800
       Property Plant Equipment 
128,492
127,238
113,521
107,364
0
0
00107,364113,521127,238128,492
> Total Liabilities 
0
0
596,121
345,309
231,164
280,845
280,845231,164345,309596,12100
   > Total Current Liabilities 
488,062
807,088
560,809
309,737
193,838
228,590
228,590193,838309,737560,809807,088488,062
       Short Long Term Debt 
0
0
91,368
86,910
123,702
139,517
139,517123,70286,91091,36800
       Accounts payable 
358,647
663,683
426,373
127,962
31,477
71,788
71,78831,477127,962426,373663,683358,647
       Other Current Liabilities 
12,665
12,993
12,861
94,865
33,952
10,572
10,57233,95294,86512,86112,99312,665
   > Long-term Liabilities 
0
0
35,312
35,534
37,326
52,256
52,25637,32635,53435,31200
       Long-term Liabilities Other 
0
0
5,413
1
-1
-1
-1-115,41300
> Total Stockholder Equity
0
0
231,564
234,846
267,663
283,606
283,606267,663234,846231,56400
   Retained Earnings 
75,713
78,955
83,026
86,308
119,125
135,068
135,068119,12586,30883,02678,95575,713
   Accumulated Other Comprehensive Income 000000
   Capital Surplus 000000
   Treasury Stock000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue589,565
Cost of Revenue-421,365
Gross Profit168,200168,200
 
Operating Income (+$)
Gross Profit168,200
Operating Expense-497,966
Operating Income91,599-329,766
 
Operating Expense (+$)
Research Development-
Selling General Administrative3,477
Selling And Marketing Expenses-
Operating Expense497,9663,477
 
Net Interest Income (+$)
Interest Income123
Interest Expense-15,794
Net Interest Income-16,685-15,671
 
Pretax Income (+$)
Operating Income91,599
Net Interest Income-16,685
Other Non-Operating Income Expenses-
Income Before Tax (EBT)22,48191,599
EBIT - interestExpense = -15,794
15,943
31,737
Interest Expense15,794
Earnings Before Interest and Taxes (ebit)-38,275
Earnings Before Interest and Taxes (ebitda)55,920
 
After tax Income (+$)
Income Before Tax22,481
Tax Provision-6,537
Net Income From Continuing Ops15,94315,943
Net Income15,943
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-16,685
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
V5W.F
3 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of V5W.F.

V5W.F Daily Candlestick Chart
UXI4.F
4 minutes ago

I found you a MACD Bearish Reversal Divergence on the daily chart of UXI4.F.

UXI4.F Daily Candlestick Chart
UT8.F
4 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of UT8.F.

UT8.F Daily Candlestick Chart
U1DA.F
8 minutes ago

I found you a RSI Bearish Hidden Divergence on the daily chart of U1DA.F.

U1DA.F Daily Candlestick Chart
TM4C.F
12 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of TM4C.F.

TM4C.F Daily Candlestick Chart
TMV.F
12 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of TMV.F.

TMV.F Daily Candlestick Chart
TL01.F
12 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TL01.F.

TL01.F Daily Candlestick Chart
TCA.F
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TCA.F.

TCA.F Daily Candlestick Chart
T5O.F
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of T5O.F.

T5O.F Daily Candlestick Chart
T0J.F
17 minutes ago

I found you a Golden Cross on the daily chart of T0J.F.

T0J.F Daily Candlestick Chart
SSU.F
19 minutes ago

I found you a Golden Cross on the daily chart of SSU.F.

SSU.F Daily Candlestick Chart
SND.F
21 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SND.F.

SND.F Daily Candlestick Chart
JEDI.XETRA
21 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JEDI.XETRA.

JEDI.XETRA Daily Candlestick Chart
PANR.LSE
21 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PANR.LSE.

PANR.LSE Daily Candlestick Chart
XFRM.LSE
22 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XFRM.LSE.

XFRM.LSE Daily Candlestick Chart
XB0T.XETRA
22 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XB0T.XETRA.

XB0T.XETRA Daily Candlestick Chart
WAXG.XETRA
22 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of WAXG.XETRA.

WAXG.XETRA Daily Candlestick Chart
UIMS.XETRA
22 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of UIMS.XETRA.

UIMS.XETRA Daily Candlestick Chart
LGGA.XETRA
22 minutes ago

I found you a Golden Cross on the daily chart of LGGA.XETRA.

LGGA.XETRA Daily Candlestick Chart
XDUS.LSE
23 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XDUS.LSE.

XDUS.LSE Daily Candlestick Chart
FLXP.XETRA
23 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FLXP.XETRA.

FLXP.XETRA Daily Candlestick Chart
XEPA.XETRA
23 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XEPA.XETRA.

XEPA.XETRA Daily Candlestick Chart
V3YL.XETRA
24 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3YL.XETRA.

V3YL.XETRA Daily Candlestick Chart
V3YA.XETRA
24 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3YA.XETRA.

V3YA.XETRA Daily Candlestick Chart
V3DA.XETRA
24 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3DA.XETRA.

V3DA.XETRA Daily Candlestick Chart